介入栓塞化疗联合索拉非尼治疗肢体腺泡状软组织肉瘤9例分析

Chinese Journal of Practical Surgery ›› 2013, Vol. 33 ›› Issue (02) : 130-132.

Chinese Journal of Practical Surgery ›› 2013, Vol. 33 ›› Issue (02) : 130-132.
论著

Author information +
History +

Abstract

Interventional therapy plus sorafenib in patients with limbs alveolar soft tissue sarcoma:a report of 9 cases                 HE Xin-hong, LI Wen-tao, PENG Wei-jun, et al. Department of Radiology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University,Shanghai 200032, China
Corresponding author: LI Wen-tao , E-mail:wentao.li.sh@gmail.com
Abstract    Objective    To evaluate the efficacy and safety of interventional therapy combined with sorafenib in patients with limbs alveolar soft tissue sarcoma. Methods    The clinical data of 9 cases of advanced limbs alveolar soft tissue sarcoma admitted between July 2007 and July 2010 in Fudan University Shanghai Cancer Center were analyzed retrospectively. All cases were obtained artery interventional embolism chemotherapy combined with sorafenib therapy. The efficacy, safety and prognosis survival situation were analyzed. Results    After interventional embolism chemotherapy and sorafenib therapy, limbs primary lesions were not reduced significantly by MRI follow-up. But focal necrosis liquefied obviously and subjective symptoms improved including the pain relief or painkillers decrement, walking disorder or body activities obstacles eased. For the patients with lung or liver metastasis, the metastatic lesions got effective control, haemoptysis and cyanosis symptoms were alleviated obviously, and outdoor activities were increased. For the patients with multiple bone metastases, the bone pain symptoms have no obvious relief, and painkillers were still need to maintenance therapy. No serious adverse reaction related to interventional embolism chemotherapy and sorafenib therapy was observed in all patients, which needn’t adjustment of dose or interrupt treatment. Conclusion Interventional therapy combined with sorafenib therapy can relieve the tumor local symptoms and tumor related complications, improve quality of life significantly in patients with advanced limbs alveolar soft tissue sarcoma. The short-term survival benefit is good. It can be used as important supplement of the treatment for advanced limbs alveolar soft tissue sarcoma.

Key words

alveolar soft tissue sarcoma / interventional therapy / sorafenib / molecular targeted therapy

Cite this article

Download Citations

Accesses

Citation

Detail

Sections
Recommended

/